<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36680082</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Long Covid: Untangling the Complex Syndrome and the Search for Therapeutics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">42</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15010042</ELocationID><Abstract><AbstractText>Long Covid can affect anyone who has previously had acute COVID-19. The root causes of this syndrome are still unknown, and no effective therapeutics are available. This complex syndrome, with a wide array of symptoms, is still evolving. Given the dire situation, it is important to identify the causes of Long Covid and the changes occurring within the immune system of affected patients to figure out how to treat it. The immune system intersects with the persistent viral fragments and blood clots that are implicated in this syndrome; understanding how these complex systems interact may help in untangling the puzzling physiopathology of Long Covid and identifying mitigation measures to provide patients some relief. In this paper, we discuss evidence-based findings and formulate hypotheses on the mechanisms underlying Long Covid's physiopathology and propose potential therapeutic options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Azizul</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3772-9773</Identifier><AffiliationInfo><Affiliation>One Medical Center Drive, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pant</LastName><ForeName>Anudeep B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0002-9497-7343</Identifier><AffiliationInfo><Affiliation>New Orleans East Hospital, New Orleans, LA 70127, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long Covid</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. All authors concur with the submission of the manuscript and none of the materials included in this manuscript have been published or are under consideration for publication elsewhere. The authors received no specific funding for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36680082</ArticleId><ArticleId IdType="pmc">PMC9864843</ArticleId><ArticleId IdType="doi">10.3390/v15010042</ArticleId><ArticleId IdType="pii">v15010042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus Disease (COVID-19): Post COVID-19 Condition.  [(accessed on 23 September 2022)].  Available online:  https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.</Citation></Reference><Reference><Citation>CDC  Long COVID or Post-COVID Conditions. Centers for Disease Control and Prevention.  [(accessed on 23 September 2022)];2022  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Hanson S.W., Abbafati C., Aerts J.G., Al-Aly Z., Ashbaugh C., Ballouz T., Blyuss O., Bobkova P., Bonsel G., et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie C.E., Lowe D.J., McAuley A., Winter A.J., Mills N.L., Black C., Scott J.T., O&#x2019;Donnell C.A., Blane D.N., Browne S., et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat. Commun. 2022;13:5663. doi: 10.1038/s41467-022-33415-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nearly One in Five American Adults Who Have Had COVID-19 Still Have &#x201c;Long COVID&#x201d;.  [(accessed on 26 October 2022)];2022  Available online:  https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm.</Citation></Reference><Reference><Citation>Long COVID.  [(accessed on 26 October 2022)];2022  Available online:  https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.</Citation></Reference><Reference><Citation>Wise J. COVID-19: WHO Urges Action as 17 Million Long COVID Cases Are Estimated in Europe.  [(accessed on 16 September 2022)];BMJ. 2022 378:o2232. doi: 10.1136/bmj.o2232. Available online:  https://www.bmj.com/content/378/bmj.o2232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o2232</ArticleId><ArticleId IdType="pubmed">36104031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Pawelek P. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK&#x2014;Office for National Statistics.  [(accessed on 26 October 2022)];2022  Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6october2022.</Citation></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M. Self-Reported Long COVID after Infection with the Omicron Variant in the UK&#x2014;Office for National Statistics.  [(accessed on 16 September 2022)];2022  Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/18july2022.</Citation></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., Taverner T., Chandan J.S., Brown K., Simms-Williams N., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., Beaufils E., Bourbao-Tournois C., Laribi S., Flament T., Ferreira-Maldent N., Bruy&#xe8;re F., Stefic K., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021;27:258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>JJacobs L.G., Paleoudis E.G., Bari D.L.-D., Nyirenda T., Friedman T., Gupta A., Rasouli L., Zetkulic M., Balani B., Ogedegbe C., et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS ONE. 2020;15:e0243882. doi: 10.1371/journal.pone.0243882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243882</ArticleId><ArticleId IdType="pmc">PMC7732078</ArticleId><ArticleId IdType="pubmed">33306721</ArticleId></ArticleIdList></Reference><Reference><Citation>Daitch V., Yelin D., Awwad M., Guaraldi G., Mili&#x107; J., Mussini C., Falcone M., Tiseo G., Carrozzi L., Pistelli F., et al. Characteristics of long-COVID among older adults: A cross-sectional study. Int. J. Infect. Dis. 2022;125:287&#x2013;293. doi: 10.1016/j.ijid.2022.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.09.035</ArticleId><ArticleId IdType="pubmed">36191820</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D., Chalon P., Kohn L., Dauvrin M., Detollenaere J., de Noordhout C.M., Jong C.P.-D., Cleemput I., Heede K.V.D. Pathophysiology and mechanism of long COVID: A comprehensive review. Ann. Med. 2022;54:1473&#x2013;1487. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere J.J., Serafini R.A., Pryce K.D., Zazhytska M., Oishi K., Golynker I., Panis M., Zimering J., Horiuchi S., Hoagland D.A., et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery. Sci. Transl. Med. 2022;14:eabq3059. doi: 10.1126/scitranslmed.abq3059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abq3059</ArticleId><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D., Stein S., Ramelli S., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C., Dickey J., Ylaya K., et al.  SARS-CoV-2 Infection and Persistence Throughout the Human Body and Brain. Res. Square. 2021.  [(accessed on 16 September 2022)].  Available online:  https://www.researchsquare.com/article/rs-1139035/latest.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A., Koch R., Jukic A., Pfister A., Meyer M., R&#xf6;ssler A., Kimpel J., Adolph T.E., Tilg H. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022;163:495&#x2013;506.e8. doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Voleti N., Reddy S.P., Ssentongo P. Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis. Front. Cardiovasc. Med. 2022;9:951314. doi: 10.3389/fcvm.2022.951314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.951314</ArticleId><ArticleId IdType="pmc">PMC9467278</ArticleId><ArticleId IdType="pubmed">36105535</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., Kell D.B. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G.J., Kotze M.J., Oladejo S.O., Watson L.R., Rajaratnam K., Watson B.W., Kell D.B. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) Cardiovasc. Diabetol. 2022;21:148. doi: 10.1186/s12933-022-01579-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Janardhan V., Janardhan V., Kalousek V. COVID-19 as a Blood Clotting Disorder Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic Implications for Stroke Thrombectomy. J. Neuroimaging. 2020;30:555&#x2013;561. doi: 10.1111/jon.12770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.12770</ArticleId><ArticleId IdType="pmc">PMC7436381</ArticleId><ArticleId IdType="pubmed">32776617</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. What Causes Long Covid? Here Are the Three Leading Theories.  [(accessed on 16 September 2022)];Science. 2022  Available online:  https://www.science.org/content/article/what-causes-long-covid-three-leading-theories.</Citation></Reference><Reference><Citation>Willyard C. Could tiny blood clots cause long COVID&#x2019;s puzzling symptoms? Nature. 2022;608:662&#x2013;664. doi: 10.1038/d41586-022-02286-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02286-7</ArticleId><ArticleId IdType="pubmed">36002482</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelen M.M., Vandenbriele C., Balthazar T., Claeys E., Gunst J., Guler I., Jacquemin M., Janssens S., Lorent N., Liesenborghs L., et al. Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. Semin. Thromb Hemost. 2021;47:362&#x2013;371. doi: 10.1055/s-0041-1727284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1727284</ArticleId><ArticleId IdType="pubmed">33893631</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L.N., Whyte M.B., Georgiou L., Giron G., Czuprynska J., Rea C., Vadher B., Patel R.K., Gee E., Arya R. Postdischarge venous thromboembolism following hospital admission with COVID-19.  [(accessed on 14 December 2022)];Blood. 2020 136:1347&#x2013;1350. doi: 10.1182/blood.2020008086. Available online:  https://ashpublications.org/blood/article/136/11/1347/461692/Postdischarge-venous-thromboembolism-following.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008086</ArticleId><ArticleId IdType="pmc">PMC7483432</ArticleId><ArticleId IdType="pubmed">32746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell R., Bogue T., Koshy A., Bindal P., Merrill M., Aird W.C., Bauer K.A., Zwicker J.I. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136:1342&#x2013;1346. doi: 10.1182/blood.2020007938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007938</ArticleId><ArticleId IdType="pmc">PMC7483433</ArticleId><ArticleId IdType="pubmed">32766883</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman D., Bonillas A., Diniz G.B., Ott S., Roh J.W., Elizaldi S.R., Schmidt B.A., Sammak R.L., Van Rompay K.K., Iyer S.S., et al.  SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19.  [(accessed on 26 October 2022)];Cell Rep. 2022 41:111573. doi: 10.1016/j.celrep.2022.111573. Available online:  http://www.cell.com/cell-reports/retrieve/pii/S2211124722014346?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124722014346%3Fshowall%3Dtrue.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111573</ArticleId><ArticleId IdType="pmc">PMC9554328</ArticleId><ArticleId IdType="pubmed">36288725</ArticleId></ArticleIdList></Reference><Reference><Citation>Holms R.D. Long COVID (PASC) Is Maintained by a Self-Sustaining Pro-Inflammatory TLR4/RAGE-Loop of S100A8/A9 &gt; TLR4/RAGE Signalling, Inducing Chronic Expression of IL-1b, IL-6 and TNFa: Anti-Inflammatory Ezrin Peptides as Potential Therapy. Immuno. 2022;2:512&#x2013;533. doi: 10.3390/immuno2030033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/immuno2030033</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-L&#xe1;zaro D., S&#xe1;nchez-Serrano N., Mielgo-Ayuso J., Garc&#xed;a-Hern&#xe1;ndez J.L., Gonz&#xe1;lez-Bernal J.J., Seco-Calvo J. Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic? J. Clin. Med. 2021;10:5799. doi: 10.3390/jcm10245799.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10245799</ArticleId><ArticleId IdType="pmc">PMC8708091</ArticleId><ArticleId IdType="pubmed">34945095</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E., Feng A., Meng W., Apostolidis S.A., Mack E., Artandi M., Barman L., Bennett K., Chakraborty S., Chang I., et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021;12:5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., Wan Y., Chung A.C.K., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159:944&#x2013;955.e8. doi: 10.1053/j.gastro.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B., Boustani K., Ogger P.P., Papadaki A., Tonkin J., Orton C.M., Ghai P., Suveizdyte K., Hewitt R.J., Desai S.R., et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity. 2022;55:542&#x2013;556.e5. doi: 10.1016/j.immuni.2022.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.01.017</ArticleId><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature. 2021;590:29&#x2013;31. doi: 10.1038/d41586-021-00149-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00149-1</ArticleId><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., et al. Diverse Functional Autoantibodies in Patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E., Malorni W. Long COVID: To investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur. Respir. J. 2021;59:2102245. doi: 10.1183/13993003.02245-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Munblit D., De Rose C., Sinatti D., Ricchiuto A., Carfi A., Valentini P. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110:2208&#x2013;2211. doi: 10.1111/apa.15870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15870</ArticleId><ArticleId IdType="pmc">PMC8251440</ArticleId><ArticleId IdType="pubmed">33835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanov I.M., Spiridonova E., Bobkova P., Gamirova A., Shikhaleva A., Andreeva M., Blyuss O., El-Taravi Y., DunnGalvin A., Comberiati P., et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 2021;59:2101341. doi: 10.1183/13993003.01341-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01341-2021</ArticleId><ArticleId IdType="pmc">PMC8576804</ArticleId><ArticleId IdType="pubmed">34210789</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani G., Verlato G., Bertino E., Maiocco G., Vesentini R., Spadavecchia A., Dess&#xec; A., Fanos V. Long COVID-19 in children: An Italian cohort study. Ital. J. Pediatr. 2022;48:83. doi: 10.1186/s13052-022-01282-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-022-01282-x</ArticleId><ArticleId IdType="pmc">PMC9163526</ArticleId><ArticleId IdType="pubmed">35659358</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Di Giuda D., Sigfrid L., Pizzuto D.A., Di Sante G., De Rose C., Lazzareschi I., Sali M., Baldi F., Chieffo D.P.R., et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc. Health. 2021;5:677&#x2013;680. doi: 10.1016/S2352-4642(21)00196-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00196-6</ArticleId><ArticleId IdType="pmc">PMC8324416</ArticleId><ArticleId IdType="pubmed">34339624</ArticleId></ArticleIdList></Reference><Reference><Citation>Pel&#xe0; G., Goldoni M., Solinas E., Cavalli C., Tagliaferri S., Ranzieri S., Frizzelli A., Marchi L., Mori P.A., Majori M., et al. Sex-Related Differences in Long-COVID-19 Syndrome. J. Women&#x2019;s Health. 2022;31:620&#x2013;630. doi: 10.1089/jwh.2021.0411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2021.0411</ArticleId><ArticleId IdType="pubmed">35333613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabra L., Klein C.R.  Sex Hormones and Immunity to Infection. Springer; Berlin/Heidelberg, Germany: 2020.  [(accessed on 22 September 2022)]. 10p.  Available online:  https://link.springer.com/book/10.1007/978-3-642-02155-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-02155-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis M.L., Maselli A., Pagano M.T., Pierdominici M., Ortona E. Immune Response and Autoimmune Diseases: A Matter of Sex.  [(accessed on 22 September 2022)];Ital. J. Gynaecol. Obstet. 2019 5:11&#x2013;20. Available online:  https://www.gendermedjournal.it/archivio/3148/articoli/31294/</Citation></Reference><Reference><Citation>Jarefors S., Bennet L., You E., Forsberg P., Ekerfelt C., Berglund J., Ernerudh J. Lyme borreliosis reinfection: Might it be explained by a gender difference in immune response? Immunology. 2006;118:224&#x2013;235. doi: 10.1111/j.1365-2567.2006.02360.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2006.02360.x</ArticleId><ArticleId IdType="pmc">PMC1782288</ArticleId><ArticleId IdType="pubmed">16771857</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadakedath S., Kandi V., Mohapatra R.K., Pinnelli V.B.K., Yegurla R.R., Shahapur P.R., Godishala V., Natesan S., Vora K.S., Sharun K., et al. Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): A scoping review. J. Med. Virol. 2021;93:5295&#x2013;5309. doi: 10.1002/jmv.27081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27081</ArticleId><ArticleId IdType="pmc">PMC8242919</ArticleId><ArticleId IdType="pubmed">33990972</ArticleId></ArticleIdList></Reference><Reference><Citation>Angum F., Khan T., Kaler J., Siddiqui L., Hussain A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020;12:e8094. doi: 10.7759/cureus.8094.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.8094</ArticleId><ArticleId IdType="pmc">PMC7292717</ArticleId><ArticleId IdType="pubmed">32542149</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deeks S.G., Mustapic M., Kapogiannis D., Henrich T.J., Lu S., Goldberg S.A., Hoh R., Chen J.Y., Martinez E.O., et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann. Neurol. 2022;91:772&#x2013;781. doi: 10.1002/ana.26350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., Senussi Y., Manickas-Hill Z., Yu X.G., Li J.Z., Alter G., Walt D.R. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated with Post-acute Coronavirus Disease 2019 Sequelae. Clin. Infect. Dis. 2022 doi: 10.1093/cid/ciac722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Zlitni S., Brooks E.F., Vance S.E., Dahlen A., Hedlin H., Park R.M., Han A., Schmidtke D.T., Verma R., et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371&#x2013;387.e9. doi: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., Pozzi C., Mollura M., Mantovani A., Rescigno M. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022;328:676&#x2013;678. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. Eclinicalmedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C. Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. Expert Rev. Hematol. 2022;15:597&#x2013;605. doi: 10.1080/17474086.2022.2098104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2022.2098104</ArticleId><ArticleId IdType="pubmed">35786377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Zhou X., Wu Q., Zhang X., Feng Z., et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann. Med. 2022;54:516&#x2013;523. doi: 10.1080/07853890.2022.2034936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon K.H., Leist S.R., Okuda K., Dang H., Fritch E.J., Gully K.L., De la Cruz G., Evangelista M.D., Asakura T., Gilmore R.C., et al. SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Sci. Transl. Med. 2022;14:eabo5070. doi: 10.1126/scitranslmed.abo5070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5070</ArticleId><ArticleId IdType="pmc">PMC9273046</ArticleId><ArticleId IdType="pubmed">35857635</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin H.D. Paxlovid Drug Interaction Screening Checklist Updated. JAMA. 2022;328:1290. doi: 10.1001/jama.2022.15442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.15442</ArticleId><ArticleId IdType="pubmed">36194234</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Advancing Translational Sciences (NCATS)   NIH Begins Large Clinical Trial to Test IMMUNE Modulators for Treatment of COVID-19. National Institutes of Health (NIH); Bethesda, MD, USA: 2020.  [(accessed on 19 September 2022)].  Available online:  https://www.nih.gov/news-events/news-releases/nih-begins-large-clinical-trial-test-immune-modulators-treatment-covid-19.</Citation></Reference><Reference><Citation>National Institutes of Health (NIH)   Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19. National Institutes of Health (NIH); Bethesda, MD, USA: 2022.  [(accessed on 19 September 2022)].  Available online:  https://www.nih.gov/news-events/news-releases/immune-modulator-drugs-improved-survival-people-hospitalized-covid-19.</Citation></Reference><Reference><Citation>Andersen K.M., Bates B.A., Rashidi E.S., Olex A.L., Mannon R.B., Patel R.C., Singh J., Sun J., Auwaerter P.G., Ng D.K., et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2021;4:e33&#x2013;e41. doi: 10.1016/S2665-9913(21)00325-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00325-8</ArticleId><ArticleId IdType="pmc">PMC8592562</ArticleId><ArticleId IdType="pubmed">34806036</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto M.D., Lambert N., Downs C.A., Abrahim H., Hughes T.D., Rahmani A.M., Burton C.W., Chakraborty R. Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection. J. Nurse Pract. 2022;18:335&#x2013;338. doi: 10.1016/j.nurpra.2021.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurpra.2021.12.016</ArticleId><ArticleId IdType="pmc">PMC8820139</ArticleId><ArticleId IdType="pubmed">35153633</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2021;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Phase 2 Study of RSLV-132 in Subjects with Long COVID.  [(accessed on 19 September 2022)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT04944121?term=NCT04944121&amp;draw=2&amp;rank=1.</Citation></Reference><Reference><Citation>Queiroz M.A.F., das Neves P.F.M., Lima S.S., Lopes J.D.C., Torres M.K.D.S., Vallinoto I.M.V.C., Bichara C.D.A., dos Santos E.F., de Brito M.T.F.M., da Silva A.L.S., et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell. Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque A., Hober D., Blondiaux J. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob. Agents Chemother. 2015;59:5892&#x2013;5902. doi: 10.1128/AAC.01105-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01105-15</ArticleId><ArticleId IdType="pmc">PMC4576072</ArticleId><ArticleId IdType="pubmed">26248374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci G., Rinaldi V., Buscarinu M.C., Reni&#xe8; R., Bigi R., Pellicciari G., Morena E., Romano C., Marrone A., Mechelli R., et al. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Front. Immunol. 2021;12:755333. doi: 10.3389/fimmu.2021.755333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.755333</ArticleId><ArticleId IdType="pmc">PMC8503550</ArticleId><ArticleId IdType="pubmed">34646278</ArticleId></ArticleIdList></Reference><Reference><Citation>Drayman N., DeMarco J.K., Jones K.A., Azizi S.-A., Froggatt H.M., Tan K., Maltseva N.I., Chen S., Nicolaescu V., Dvorkin S., et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373:931&#x2013;936. doi: 10.1126/science.abg5827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg5827</ArticleId><ArticleId IdType="pmc">PMC8809056</ArticleId><ArticleId IdType="pubmed">34285133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>